Abstract: In 2025, China's biopharmaceutical industry entered a new stage of value creation driven by innovation, reform, and openness. Looking ahead to 2026, the biopharmaceutical sector will strengthen the leading role of scientific and technological innovation, accelerate industrial transformation and upgrading, and build a high-quality development landscape. Through multiple rounds of brainstorming roundtables, Shanghai Center for Innovation Drug Discovery and Development(SCIDDD) proposed that China's biopharmaceutical industry needs to continuously enhance its value creation capabilities, accelerate the globalization process, and unswervingly follow the path of high-quality development.